

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM788318

|   |                              |                       |                    |
|---|------------------------------|-----------------------|--------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT               |                       |                    |
| <b>NATURE OF CONVEYANCE:</b>  | RELEASE OF SECURITY INTEREST |                       |                    |
| <b>CONVEYING PARTY DATA</b>   |                              |                       |                    |
| <b>Name</b>   | <b>Formerly</b>              | <b>Execution Date</b> | <b>Entity Type</b> |
| CANADIAN IMPERIAL BANK OF COMMERCE  |                              | 02/03/2023            | Chartered Bank:    |
| <b>RECEIVING PARTY DATA</b>   |                              |                       |                    |
| <b>Name:</b>  | CIPHER PHARMACEUTICALS INC.  |                       |                    |
| <b>Street Address:</b>  | 5650 Tomken Road             |                       |                    |
| <b>Internal Address:</b>  | Unit 16                      |                       |                    |
| <b>City:</b>  | Mississauga                  |                       |                    |
| <b>State/Country:</b>   | CANADA                       |                       |                    |
| <b>Postal Code:</b>   | L4W 4P1                      |                       |                    |
| <b>Entity Type:</b>   | Corporation: CANADA          |                       |                    |
| <b>PROPERTY NUMBERS Total: 1</b>  |                              |                       |                    |
| <b>Property Type</b>  | <b>Number</b>                | <b>Word Mark</b>      |                    |
| <b>Registration Number:</b>   | 3403114                      | LIPOFEN               |                    |
| <b>CORRESPONDENCE DATA</b>  |                              |                       |                    |
| <b>Fax Number:</b>  | 4169418852                   |                       |                    |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                              |                       |                    |
| <b>Phone:</b>   | 613 842-4299                 |                       |                    |
| <b>Email:</b>   | ederenyi@foglers.com         |                       |                    |
| <b>Correspondent Name:</b>  | Eugene Derenyi               |                       |                    |
| <b>Address Line 1:</b>  | 77 King St. W                |                       |                    |
| <b>Address Line 2:</b>  | Suite 3000                   |                       |                    |
| <b>Address Line 4:</b>  | Toronto, CANADA M5K 1G8      |                       |                    |
| <b>NAME OF SUBMITTER:</b>   | Eugene Derenyi               |                       |                    |
| <b>SIGNATURE:</b>   | /Eugene Derenyi/             |                       |                    |
| <b>DATE SIGNED:</b>   | 02/21/2023                   |                       |                    |
| <b>Total Attachments: 4</b>   |                              |                       |                    |
| source=Release#page1.tif  |                              |                       |                    |
| source=Release#page2.tif  |                              |                       |                    |
| source=Release#page3.tif  |                              |                       |                    |

OP \$40.00 3403114



**RELEASE AND DISCHARGE OF SECURITY INTEREST IN INTELLECTUAL  
PROPERTY**

**THIS DISCHARGE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY** (this "**Discharge**") is made as of February 3 , 2023 ("**Effective Date**") by and between CANADIAN IMPERIAL BANK OF COMMERCE ("**CIBC**") and CIPHER PHARMACEUTICALS INC. ("**Cipher**").

**WHEREAS** a certain credit agreement was entered into amongst, inter alios, Cipher, as borrower, and CIBC, as lender, dated November 3, 2017 (as amended, amended and restated, renewed, extended, supplemented, replaced or otherwise modified from time to time, the "**Credit Agreement**") pursuant to which Cipher was indebted and obligated to CIBC.

**AND WHEREAS**, pursuant to such Credit Agreement, CIBC and Cipher executed a security agreement dated November 3, 2017 (as amended, amended and restated, renewed, extended, supplemented, replaced or otherwise modified from time to time, the "**Security Document**") whereby Cipher granted to CIBC for its benefit, among other things, a security interest in Cipher's Canadian and United States trademark registrations as listed in Schedule A attached hereto (the "**Scheduled IP Collateral**");

**AND WHEREAS** the Security Document was recorded with the Canadian Intellectual Property Office ("**CIPO**") under file number 1581834;

**AND WHEREAS** the Security Document was recorded with the United States Patent and Trademark Office ("**USPTO**") under Reel/Frame number 6217/0279;

**AND WHEREAS** Cipher has paid in full all obligations outstanding under the Credit Agreement, and CIBC, at Cipher's request, agrees to release its security interest in the Scheduled IP Collateral;

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. CIBC hereby terminates, cancels, discharges, reassigns and releases to Cipher any and all liens and security interests it has against, and any and all right, title and interest it may have in or to, the Scheduled IP Collateral;
2. CIBC hereby directs CIPO to immediately remove and discharge all such liens and security interests in favour of CIBC against the applicable Scheduled IP Collateral;
3. CIBC hereby directs the USPTO to immediately remove and discharge all such liens and security interests in favour of CIBC against the applicable Scheduled IP Collateral;
4. CIBC hereby directs Fogler, Rubinoff LLP or its designees, to perform all acts required in order to obtain such removal and discharge by CIPO and the USPTO of such liens and security interests in favour of CIBC against the Scheduled IP Collateral; and
5. CIBC shall, at Cipher's expense, take all further actions, and provide to Cipher, its successors, assigns or other legal representatives, all such cooperation and assistance

(including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by Cipher to more fully and effectively effectuate the purposes of this Discharge.

This Discharge may be executed by facsimile, e-mail or other functionally equivalent electronic means of transmission and it shall constitute valid and effective delivery.

The undersigned parties have signed below to indicate their consent (and the consent of their successors and assigns) to be bound by the terms and conditions of this Discharge. This Discharge will be for the benefit of the addressee hereof and its successors and assigns.

*[Signature Page Follow]*

**IN WITNESS WHEREOF**, the undersigned parties have executed this Discharge as of the date first written above.

**CANADIAN IMPERIAL BANK OF COMMERCE**

By: Vikram Misra  
Name: Vikram Misra  
Title: Authorized Signatory

By: James Day  
Name: James Day  
Title: Authorized Signatory

**CIPHER PHARMACEUTICALS INC.**

By: Bjw  
Name: Bryan Jacobs, CFO  
Title:

**SCHEDULE "A"**

| <b>Canadian Trademarks</b> |                             |                    |                      |                    |
|----------------------------|-----------------------------|--------------------|----------------------|--------------------|
|                            | <b>Owner</b>                | <b>Description</b> | <b>Application #</b> | <b>Trademark #</b> |
| 1.                         | Cipher Pharmaceuticals Inc. | EPURIS             | 1581834              | TMA879439          |

| <b>US Trademarks</b> |                             |                    |                 |                       |
|----------------------|-----------------------------|--------------------|-----------------|-----------------------|
|                      | <b>Owner</b>                | <b>Description</b> | <b>Serial #</b> | <b>Registration #</b> |
| 1.                   | Cipher Pharmaceuticals Inc. | LIPOFEN            | 78688955        | 3403114               |